<DOC>
	<DOCNO>NCT03012906</DOCNO>
	<brief_summary>Patients undergo percutaneous coronary intervention ( PCI ) stent implantation require chronic anticoagulation atrial fibrillation ( AF ) CHA2DS2-VASc &gt; 1 require receive triple antithrombotic therapy . This triple therapy include dual antiplatelet therapy clopidogrel aspirin combination oral anticoagulant either vitamin K antagonist ( VKA ) oral anticoagulant ( NOAC ) . Recently NOAC , inhibit IIa ( dabigatran ) Xa ( rivaroxaban apixaban ) coagulation cascade demonstrate non inferiority compare VKA prevent thrombo-embolic event non-valvular AF patient CHA2DS2-VASc &gt; 1 . Interestingly , NOAC associate reduced fatal bleeding rate compare VKA . Overall seem result lower bleeding rate compare VKA association antiplatelet agent . Recently European guideline regard patient require chronic anticoagulant therapy undergo coronary stent implantation update . However base expert consensus scarce data available . These guideline advocate combination dual antiplatelet therapy clopidogrel aspirin combination lower dose OAC VKA target INR 2 2.5 . The triple therapy prescribe 1 6 month depend bleed thrombotic risk clinical setting . In patient high bleed risk guideline suggest sole antiplatelet agent could use addition anticoagulation follow WOEST study . In recently publish ESC guideline management atrial fibrillation , despite lack new data , expert advocate triple therapy follow dual antiplatelet therapy patient 12 month . The recently publish PIONEER study reinforce possibility use rivaroxaban patient . In trial include ACS ACS patient undergo PCI rivaroxaban 15 mg addition P2Y12 ADP receptor antagonist associate less clinically relevant bleeding compare triple therapy VKA- aspirin clopidogrel similar efficacy .</brief_summary>
	<brief_title>Registry Combination Antiplatelet Agents Anticoagulant Atrial Fibrillation Patients With CHA2DS2VASc Score &gt; 1 Undergoing Percutaneous Coronary Interventions</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>1. age 18 year old 2. sign inform consent 3. require PCI ( stent placement ) subsequent need antiplatelet therapy 4 . FA require chronic anticoagulation ( CHA2DS2VASc &gt; 1 , except woman score =1 ) . 1. pregnancy lactation 2. age &lt; 18 able give inform consent 3. informed consent 4. health insurance 5. prisoner 6. contra indication antiplatelet therapy 7. intra cardiac thrombus 8. active bleed Known bleed diathesis ( i.e . history ICH , GI bleed ) 9. severe kidney failure ( eGFR &lt; 30 mL/min/1.73 mÂ² ) 10. severe hepatic failure ( ChildPugh class B C ) 11. contra indication OAC VKA 12. hypertrophic myocardiopathy 13. valvular prosthesis 14. history peptic ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>